Table of contents
May 2005 Vol 4 No 5
In this issue
p353 | doi:10.1038/nrd1739
Editorial: More to the fore
p355 | doi:10.1038/nrd1738
News and Analysis
News
Third Tysabri adverse case hits drug class | PDF (925 KB)
p357 | doi:10.1038/nrd1743
News
Mergers in Japan help firms retain own products | PDF (925 KB)
p358 | doi:10.1038/nrd1744
News
FDA pharmacogenomics guidance sends clear message to industry | PDF (925 KB)
p359 | doi:10.1038/nrd1745
In brief
Bextra withdrawn from market | More success for Avastin | Novel Indian generics agreement | HPV vaccine effective | Partnership to develop TB drugs | Cuts announced at Pfizer | Study questions effectiveness of Alzheimer's drug | Sanofi wins Plavix patent case | Success for nonprofit pharmaceutical company | PDF (925 KB)
p360 | doi:10.1038/nrd1742
News
An array of problems | PDF (925 KB)
p362 | doi:10.1038/nrd1746
Patent watch
Traditional knowledge counts as prior art | PDF (925 KB)
p364 | doi:10.1038/nrd1734
Patent watch
India bill leaves generics breathing space | PDF (925 KB)
p364 | doi:10.1038/nrd1735
Patent primer
Interferences: rights of the first inventor in the US | PDF (925 KB)
p365 | doi:10.1038/nrd1725
Robert Langer | PDF (109 KB)
p366 | doi:10.1038/nrd1747
From the analyst's couch
Type 2 diabetes market | PDF (164 KB)
p367 | doi:10.1038/nrd1723
Fresh from the Pipeline
Clofarabine | PDF (131 KB)
p369 | doi:10.1038/nrd1724
Research Highlights
G-Protein-coupled receptors: Better beta-blockers | PDF (162 KB)
p371 | doi:10.1038/nrd1713
Drug delivery: Principles of penetration | PDF (388 KB)
p372 | doi:10.1038/nrd1732
Gene therapy: Permanent correction without selection | PDF (236 KB)
p372 | doi:10.1038/nrd1736
Proteases: Joint advantage | PDF (213 KB)
p373 | doi:10.1038/nrd1740
Cardiovascular disease: New use for cannabinoids | PDF (180 KB)
p374 | doi:10.1038/nrd1733
In brief
Kinases | Malaria | Immunotherapy | Imaging | PDF (180 KB)
p374 | doi:10.1038/nrd1741
Perspectives
Outlook
Cancer drug discovery through collaboration
Christoph Lengauer, Luis A. Diaz, Jr & Saurabh Saha
p375 | doi:10.1038/nrd1722
Timeline
The rise and rise of drug delivery
Howard Rosen & Thierry Abribat
p381 | doi:10.1038/nrd1721
Reviews
Rho kinase, a promising drug target for neurological disorders
Bernhard K. Mueller, Helmut Mack & Nicole Teusch
p387 | doi:10.1038/nrd1719
Regulators of apoptosis: suitable targets for immune therapy of cancer
Mads Hald Andersen, Jürgen C. Becker & Per thor Straten
p399 | doi:10.1038/nrd1717
Elucidating mechanisms of drug-induced toxicity
Daniel C. Liebler & F. Peter Guengerich
p410 | doi:10.1038/nrd1720
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Prakash Jagtap & Csaba Szabó
p421 | doi:10.1038/nrd1718
